|  |
| --- |
| **Supplementary** **Table 3.** Summary of TEAEs of abnormal peripheral sensationthrough week 80 (treatment + follow-up periods) |
| **N (%) of patients** | **Tanezumab****5 mg** **(n = 92)** | **Tanezumab****10 mg** **(n = 93)** | **Celecoxib****200 mg****(n = 92)** |
| Any TEAE | 10 (10.9) | 5 (5.4) | 7 (7.6) |
| Specific TEAE\* Hypoesthesia Carpal tunnel syndrome Dysesthesia Neuralgia Sciatica Paresthesia | 6 (6.5)1 (1.1)1 (1.1)1 (1.1)1 (1.1)0 | 3 (3.2)2 (2.2)0001 (1.1) | 5 (5.4)0002 (2.2)0 |
| Terms included in this analysis were: allodynia; axonal neuropathy; burning sensation; carpal tunnel syndrome; decreased vibratory sense; demyelinating polyneuropathy; dysesthesia; formication; hyperesthesia; hyperpathia; hypoesthesia; hypoesthesia oral; intercostal neuralgia; neuralgia; neuritis; neuropathy peripheral; paresthesia; paresthesia oral; peripheral sensorimotor neuropathy; peripheral sensory neuropathy; polyneuropathy; polyneuropathy chronic; sciatica; sensory disturbance; sensory loss; tarsal tunnel syndrome; thermohypoesthesia.\*Patients could have more than one specific TEAE of abnormal peripheral sensation. TEAE = treatment-emergent adverse event.  |